Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Athersys Inc 3201 CARNEGIE AVENUE CLEVELAND OH 44115 USA

P: 216-431-9900 F: 216-361-9495

Description:

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).

Key Statistics

Overview:

Market Capitalization, $K 233,651
Shares Outstanding, K 149,776
Annual Sales, $ 24,290 K
Annual Net Income, $ -24,280 K
Last Quarter Sales, $ 1,450 K
Last Quarter Net Income, $ -12,960 K
60-Month Beta 0.32
% of Insider Shareholders 15.31%
% of Institutional Shareholders 19.60%
Float, K 126,845
% Float 84.69%

Growth:

1-Year Return -24.81%
3-Year Return -27.44%
5-Year Return -7.14%
5-Year Revenue Growth 895.49%
5-Year Earnings Growth 60.87%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/07/19
Earnings Per Share ttm -0.19
EPS Growth vs. Prev Qtr -12.50%
EPS Growth vs. Prev Year -12.50%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

ATHX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -10.14
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -58.10
Return-on-Assets (Before Tax) -41.66
Profit Margin % -99.96
Net Margin % -119.89
Debt/Equity 0.00
Price/Sales 10.11
Price/Cash Flow N/A
Price/Book 6.64
Book Value/Share 0.25
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar